IMNM
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
Article Summary
HOLD- Immunome Inc. (Nasdaq: IMNM) announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with F AP-expressing advanced solid tumors.
- The biotechnology company committed to developing first- in class and best in class targeted cancer therapies designed to deliver radioactive lutetium-177 directly to fibroblast activation protein (FAP), where emitted beta particles may damage or kill nearby tumor cells through bystander effect.
- The Phase 1 trial is an open-label multicenter multicenter dose escalation and expansion study designed to determine safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity in participants with advanced tumors, with the dose escalation portion evaluating escalating repeated doses to determine maximum tolerated dose and recommended expansion dose, and the expansion portion designed to further evaluate safety and tolerability at candidate recommended dose.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -63.3% | 25% | 0.0 ptsDeclining (-63.3%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 22.6% | 25% | 70.0 ptsGood (22.6%) - Solid outlook |
| Target Price Upside ? | 61.9% | 20% | 100.0 ptsMassive Upside (61.9%) - Target: $35.77 vs Current: $22.09 |
| Gross Margin % ? | 25.7% | 15% | 40.0 ptsModerate (25.7%) - Adequate margins |
| Drawdown from 52-Wk High ? | -20.1% | 15% | 40.0 ptsMild Pullback (-20.1%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About IMNM
- Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
- The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
- It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.
- Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.